« Back to Record
Citation APA

Van Cutsem, E., Cunningham, D., ten Bokkel Huinink, W., Punt, C., Alexopoulos, C., Dirix, L. Y., Symann, M., Blijham, G., Cholet, P., Fillet, G., Van Groeningen, C., Vannetzel, J. M., Lévi, F., Panagos, G., Unger, C., Wils, J., Cote, C., Blanc, C., Herait, P., & Bleiberg, H. (1999). Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). European journal of cancer, 35(1), 54-59. doi:10.1016/S0959-8049(98)00353-0


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/90306

Van Cutsem, E., Cunningham, D., ten Bokkel Huinink, W., Punt, C., Alexopoulos, C., Dirix, L. Y., Symann, M., Blijham, G., Cholet, P., Fillet, G., Van Groeningen, C., Vannetzel, J. M., Lévi, F., Panagos, G., Unger, C., Wils, J., Cote, C., Blanc, C., Herait, P., & Bleiberg, H. (1999). Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). European journal of cancer, 35(1), 54-59. doi:10.1016/S0959-8049(98)00353-0